



Chief Scientific Officer Dr. J. Christopher Hall (far left) explains PlantForm's technology platform to Hon. Reza Moridi, Minister of Research and Innovation, (centre) April 3. Looking on are PlantForm's Dr. Mike McLean, Director Research; Dr. Don Stewart, President and CEO; and Ron Hosking, Chief Financial Officer (from left to right).

FOR IMMEDIATE RELEASE

Minister's visit spotlights PlantForm innovation

Ontario Minister of Research and Innovation meets with PlantForm officials, tours facility

GUELPH, Ont., April 3, 2013—The Honourable Reza Moridi, Minister of Research and Innovation, met with PlantForm officials and toured the company's research facility in Guelph today.

"Our meeting with Minister Moridi was an excellent opportunity to discuss the company's progress and how our ultra-low-cost manufacturing process will lead to more affordable biologic drugs for cancer and other diseases," said Dr. Don Stewart, PlantForm President and CEO.

"As the new Minister of Research and Innovation, I have been touring the province, meeting with stakeholders and seeing the world-class innovation that takes place right here in Ontario," said Minister Moridi. "It's exciting to see firsthand the research that is building the economy and creating the jobs of tomorrow."



plantformcorp.com



Minister Moridi (eighth from left) with the PlantForm management and scientific teams, and Mark Smithyes, Manager, Federal Policy, Novartis Pharmaceuticals Canada Inc. (second from left).

PlantForm Corporation was formed in 2008 to commercialize a plant-based manufacturing platform for low-cost monoclonal antibodies, protein drugs and vaccines that target cancer and other critical illnesses. PlantForm licenses its technology from the **University of Guelph**, where it was developed by **Dr. J. Christopher Hall**, the Canada Research Chair in Recombinant Antibody Technology. Dr. Hall is a PlantForm founder and the company's Chief Scientific Officer. All relevant intellectual property is protected by patent filings.

The company is currently raising Series A capital to advance into the regulatory approval process for its first antibody product, a biosimilar version of the breast cancer drug Herceptin[®] (trastuzumab). Two additional biosimilar antibody drugs for cancer are in development, as are antibodies for the treatment of human immunodeficiency virus. Research is also under way on an enzyme to protect against nerve agent exposure, funded by the **U.S. Defense Advanced Research Projects Agency**.

-30-

For more information, please contact:

Don Stewart
President and CEO

don.stewart@plantformcorp.com
(416) 452-7242

Stacey Curry Gunn
Director of Communications

stacey.curry.gunn@plantformcorp.com
(519) 827-1131